查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
基因治疗市场机会与预测（2017-2031）：按类型、载体、基因传递方法、应用、给药途径、最终用户和地区
市场调查报告书
商品编码
1422064

基因治疗市场机会与预测（2017-2031）：按类型、载体、基因传递方法、应用、给药途径、最终用户和地区

Gene Therapy Market Assessment, By Type, By Vector, By Gene Delivery Method, By Application, By Route of Administration, By End-users, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 227 Pages | 商品交期: 3-5个工作天内

价格

全球基因治疗市场规模预计将从 2023 年的 76.4 亿美元增至 2031 年的 378.3 亿美元，预测期内复合年增长率为 22.13%。

全球基因治疗市场受到多种因素的推动，包括基因编辑技术的创新、基因治疗数量的增加、个性化医疗的日益普及、製造工艺的进步以及更快的监管审批流程，呈现出稳步扩张的趋势。

由于 CRISPR-Cas9 和 TALEN 等基因编辑技术的进步，全球基因疗法市场目前正在快速扩张，彻底改变了基因治疗的精确度和效率。 随着越来越多的候选基因疗法正在开发中，可治疗疾病的范围不断扩大，包括罕见遗传疾病、癌症和神经退化性疾病。 全球基因治疗市场的多元化也在一定程度上受到财政支持的推动，创投、製药巨头和政府机构在研究、临床试验和商业化方面进行了大量投资。

对个人化医疗的需求不断增加

对个人化医疗日益增长的兴趣正在为全球基因治疗市场提供重大推动力。 个人化医疗着重于根据个别患者的特定基因组成和需求客製化治疗方案。 基因治疗透过根据患者的基因谱提供精确的标靶治疗策略而发挥至关重要的作用。 随着我们对遗传学和基因组学理解的进步，医疗保健提供者和患者越来越认识到基因疗法对多种遗传和罕见疾病的潜在益处。 对根据个人独特遗传特征量身定制治疗的需求不断增长，正在推动基因治疗市场的成长。 患者和医疗保健专业人员越来越多地寻求基因治疗解决方案，推动研发和投资，推动全球基因治疗市场的成长。

技术进步

人工智慧在全球基因治疗市场中扮演重要角色。 人工智慧正在被用于基因治疗研发的各个领域，包括分析广泛的基因组资料集、识别潜在的基因标靶、预测治疗结果和优化递送方法等任务。 人工智慧处理和解释复杂遗传数据的速度将加速基因治疗的发现和进步。 此外，人工智慧驱动的演算法可以根据患者独特的基因谱为个别患者量身定制治疗方案，从而帮助改善个人化基因疗法。 人工智慧与基因治疗研究和临床应用的整合预计将推动创新和市场扩张。

本报告调查了全球基因治疗市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司的简介等等。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球基因治疗市场展望

  • 市场规模/预测
  • 依类型
    • 基因沉默
    • 细胞更换
    • 基因增强
    • 其他
  • 按向量
    • 非病毒载体
    • 病毒载体
  • 透过基因传递法
    • 体外
    • 体内
  • 依用途
    • 肿瘤疾病
    • 神经肌肉疾病
    • 心血管疾病
    • 传染病
    • 遗传疾病
    • 血液疾病
    • 其他
  • 依给药途径
    • 静脉注射
    • 口服
    • 肌肉注射
    • 其他
  • 按最终用户
    • 医院
    • 癌症/研究机构
    • 诊所
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第 5 章全球基因治疗市场展望：依地区

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 依类型
  • 按向量
  • 透过基因传递法
  • 依用途
  • 依给药途径
  • 按最终用户
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 成长促进因素
  • 成长抑制因素（问题/障碍）

第 9 章监理架构/创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/最新技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Bristol Myers Squibb Company
  • Sarepta therapeutics Inc.
  • Novartis AG
  • Biogen Inc.
  • Gilead Sciences Inc.
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • Medtronic Inc.
  • Takeda Pharmaceutical Company
  • AstraZeneca plc

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX10929

Global gene therapy market size was valued at USD 7.64 billion in 2023, which is expected to reach USD 37.83 billion in 2031, with a CAGR of 22.13% for the forecast period between 2024 and 2031. The global gene therapy market is experiencing robust expansion, owing to various factors such as innovations in gene editing technologies, increasing volume of gene therapy, growing popularity of personalized medicine, advancements in the manufacturing process, and expediting the regulatory approval process.

The global gene therapy market is currently experiencing rapid expansion, driven by advancements in gene editing technologies, such as CRISPR-Cas9 and TALEN, which have revolutionized the precision and efficiency of gene therapy. The scope of treatable conditions continues to widen, with gene therapy candidates in development for an ever-expanding range of diseases, including rare genetic disorders, cancer, neurodegenerative conditions, and many more. The diversification of global gene therapy market is partly a result of financial support, as venture capitalists, pharmaceutical giants, and government agencies invest heavily in research, clinical trials, and commercialization.

The growing interest in personalized medicine is another driver, as gene therapy offers tailored treatment strategies based on an individual's genetic profile. It aligns with a broader trend in healthcare where patient-centric care is prioritized, increasing the demand for gene therapy. Collaborative efforts and partnerships have become pivotal in accelerating gene therapy development, with academic institutions, biotechnology firms, and pharmaceutical companies combining their resources and knowledge. The regulatory environment of global gene therapy market is becoming more friendly, with expedited review processes and flexible pathways for rare diseases and unmet medical needs. Consequently, improvements in manufacturing process have streamlined production processes, reducing costs and complexities associated with gene therapy products.

Growing Demand for Personalized Medicine

The rising interest in personalized medicine significantly boosts the global gene therapy market. Personalized medicine focuses on tailoring medical treatments to the specific genetic makeup and needs of individual patients. Gene therapy plays a pivotal role by offering precise targeted treatment strategies based on a patient's genetic profile. As the understanding of genetics and genomics continue to advance, there is a growing awareness among both healthcare providers and patients about the potential benefits of gene therapy in addressing a wide range of genetic and rare diseases. The increasing demand for treatments customized to an individual's unique genetic characteristics is a driving force behind the growth of the gene therapy market. Patients and healthcare professionals are increasingly seeking gene therapy solutions, which in turn, encourages research and development and investment, thus driving the growth of global gene therapy market.

Technological Advancements

Artificial intelligence plays a crucial role in the global gene therapy market. AI is being used in various segments of gene therapy R&D, encompassing tasks such as analyzing extensive genomic datasets, identifying potential gene targets, predicting treatment outcomes, and optimizing delivery methods. The speed at which AI can process and interpret intricate genetic data, expedites the discovery and advancement of gene therapies. Furthermore, AI-driven algorithms contribute to the refinement of personalized gene therapies, tailoring treatments to individual patients based on their unique genetic profiles. As AI advances, its integration into gene therapy research and clinical application is poised to foster innovation and market expansion.

In March 2023, Google unveiled that a group of researchers utilized Google's AI based technology, DeepMind, to create a bacterial injection system capable of directly delivering proteins, including cancer-fighting medications and gene therapies, into human cells.

Government Initiatives

Governments of many countries are increasingly taking proactive steps to promote and regulate the field of gene therapy. These initiatives encompass a range of activities, from funding research and development programs to establishing clear regulatory frameworks. Such government initiatives provide financial support for groundbreaking gene therapy research and foster an environment of safety and compliance, which is crucial for gaining public trust and industry investment. As a result, these efforts create a favorable landscape for gene therapy companies, encouraging innovation and accelerating the development of promising gene-based treatments. Government initiatives are acting as a catalyst, propelling the growth of global gene therapy market.

In February 2023, the Department of Health and Social Care and NHS England unveiled the 2023 England rare diseases action plan, demonstrating commitment towards assisting individuals affected by rare diseases. The government is introducing novel medications for those suffering from various rare conditions, encompassing life-saving gene therapies and advancements in genomic testing and sequencing technologies.

Growing Demand for Adeno-Associated Virus Vector

The increasing demand for adeno-associated virus (AAV) vectors in gene therapy is significantly propelling the global gene therapy market. AAV vectors are crucial delivery vehicles for introducing therapeutic genes into target cells and tissues. Their rising popularity can be attributed to their safety profile and effectiveness in transferring genetic material. As gene therapy continues to advance and diversify, AAV vectors are being used in different treatments for genetic and rare diseases, including inherited disorders and various forms of cancer. The growing reliance on AAV vectors is fueling the gene therapy market's growth, as researchers and biotech companies invest in their development and production.

In July 2023, Astellas entered into a substantial agreement worth USD 962 million with 4D Molecular Therapeutics, focusing on treating rare eye diseases. Under the partnership, Astellas secured the rights to utilize 4DMT's gene therapy vector for at least one specific therapeutic target. R100, an adeno-associated virus (AAV) vector developed by 4DMT, designed for intravitreal delivery.

Growth in Volume for Neuromuscular Diseases

The rising demand for gene therapy in treating neuromuscular diseases is a significant driver of the global gene therapy market. Neuromuscular disorders consist of a range of conditions affecting the nervous system and muscles, often with limited treatment options. Gene therapy offers a promising avenue for addressing these conditions by delivering functional genes to replace or repair faulty ones. As research and clinical trials continue to demonstrate the potential effectiveness of gene therapy in treating neuromuscular diseases, the demand for such therapies is growing. It in turn, fuels investment, innovation, and expansion in the gene therapy market as companies strive to meet the unmet medical needs of patients with these challenging conditions.

In June 2023, Astellas Pharma Inc. and Kate Therapeutics unveiled an exclusive licensing agreement to develop and commercialize KT430. KT430 is an advanced preclinical gene therapy, utilizing a novel MyoAAV capsid, designed to deliver a functional version of the MTM1 gene. The primary objective of the therapy is to address X-linked myotubular myopathy (XLMTM), an exceedingly severe and rare neuromuscular disorder characterized by profound muscle weakness, respiratory insufficiency, and a high risk of premature mortality.

Future Market Scenario

The future of the global gene therapy market appears promising, driven by several key factors. Ongoing advancements in gene editing technologies, such as CRISPR-Cas9 and emerging techniques, are enhancing the precision and efficiency of gene therapy. These breakthroughs enable scientists to target and modify specific genes with unprecedented accuracy, expanding the range of treatable diseases. Regulatory agencies worldwide are increasingly recognizing the potential of gene therapy and adopting more flexible and expedited review processes for these innovative treatments. It encourages greater investment and interest from pharmaceutical companies and biotech firms, spurring the development of a robust pipeline of gene therapy candidates across a wide spectrum of medical conditions. The expanding focus on personalized medicine, where treatments are tailored to an individual's genetic profile, drives gene therapy market growth.

Key Players Landscape and Outlook

In the global gene therapy market, major pharmaceutical and biotechnology companies are entering into partnerships and collaborations. These collaborations facilitate the sharing of resources, knowledge, and expertise, ultimately expediting the development and commercialization of gene therapies. For pharmaceutical giants, teaming up with innovative biotech firms allows them to diversify their portfolios and tap into innovative gene therapy solutions.

AstraZeneca disclosed on November 1, 2023, its plans to allocate USD 245 million in a strategic partnership with the French biotechnology firm Cellectis. The collaboration is focused on accelerating the advancement of therapeutics within sectors such as oncology, immunology, and rare diseases. By harnessing Cellectis' expertise in gene-editing technology and manufacturing, AstraZeneca aims to enhance its expanding portfolio of innovative cell and gene therapy products. The investment signifies AstraZeneca's commitment to fortify its presence in these critical therapeutic areas, leveraging Cellectis' capabilities to drive innovation and the development of novel treatments.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Gene Therapy Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Type
    • 4.2.1. Gene Silencing
    • 4.2.2. Cell Replacement
    • 4.2.3. Gene Augmentation
    • 4.2.4. Others
  • 4.3. By Vector
    • 4.3.1. Non-Viral Vectors
    • 4.3.2. Viral Vectors
  • 4.4. By Gene Delivery Method
    • 4.4.1. Ex vivo
    • 4.4.2. In vivo
  • 4.5. By Application
    • 4.5.1. Oncological Diseases
    • 4.5.2. Neuromuscular Diseases
    • 4.5.3. Cardiovascular Diseases
    • 4.5.4. Infectious Diseases
    • 4.5.5. Genetic Diseases
    • 4.5.6. Haematological Diseases
    • 4.5.7. Others
  • 4.6. By Route of Administration
    • 4.6.1. Intravenous
    • 4.6.2. Oral
    • 4.6.3. Intramuscular
    • 4.6.4. Others
  • 4.7. By End-users
    • 4.7.1. Hospitals
    • 4.7.2. Cancer and Research Institutes
    • 4.7.3. Clinics
    • 4.7.4. Others
  • 4.8. By Region
    • 4.8.1. North America
    • 4.8.2. Europe
    • 4.8.3. South America
    • 4.8.4. Asia-Pacific
    • 4.8.5. Middle East and Africa
  • 4.9. By Company Market Share (%), 2023

5. Global Gene Therapy Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Type
      • 5.1.2.1. Gene Silencing
      • 5.1.2.2. Cell Replacement
      • 5.1.2.3. Gene Augmentation
      • 5.1.2.4. Others
    • 5.1.3. By Vector
      • 5.1.3.1. Non-Viral Vectors
      • 5.1.3.2. Viral Vectors
    • 5.1.4. By Gene Delivery Method
      • 5.1.4.1. Ex vivo
      • 5.1.4.2. In vivo
    • 5.1.5. By Application
      • 5.1.5.1. Oncological Diseases
      • 5.1.5.2. Neuromuscular Diseases
      • 5.1.5.3. Cardiovascular Diseases
      • 5.1.5.4. Infectious Diseases
      • 5.1.5.5. Genetic Diseases
      • 5.1.5.6. Haematological Diseases
      • 5.1.5.7. Others
    • 5.1.6. By Route of Administration
      • 5.1.6.1. Intravenous
      • 5.1.6.2. Oral
      • 5.1.6.3. Intramuscular
      • 5.1.6.4. Others
    • 5.1.7. By End-users
      • 5.1.7.1. Hospitals
      • 5.1.7.2. Cancer and Research Institutes
      • 5.1.7.3. Clinics
      • 5.1.7.4. Others
    • 5.1.8. United States*
      • 5.1.8.1. Market Size & Forecast
      • 5.1.8.1.1. Value
      • 5.1.8.1.2. Volume
      • 5.1.8.2. By Type
      • 5.1.8.2.1. Gene Silencing
      • 5.1.8.2.2. Cell Replacement
      • 5.1.8.2.3. Gene Augmentation
      • 5.1.8.2.4. Others
      • 5.1.8.3. By Vector
      • 5.1.8.3.1. Non-Viral Vectors
      • 5.1.8.3.2. Viral Vectors
      • 5.1.8.4. By Gene Delivery Method
      • 5.1.8.4.1. Ex vivo
      • 5.1.8.4.2. In vivo
      • 5.1.8.5. By Application
      • 5.1.8.5.1. Oncological Diseases
      • 5.1.8.5.2. Neuromuscular Diseases
      • 5.1.8.5.3. Cardiovascular Diseases
      • 5.1.8.5.4. Infectious Diseases
      • 5.1.8.5.5. Genetic Diseases
      • 5.1.8.5.6. Haematological Diseases
      • 5.1.8.5.7. Others
      • 5.1.8.6. By Route of Administration
      • 5.1.8.6.1. Intravenous
      • 5.1.8.6.2. Oral
      • 5.1.8.6.3. Intramuscular
      • 5.1.8.6.4. Others
      • 5.1.8.7. By End-users
      • 5.1.8.7.1. Hospitals
      • 5.1.8.7.2. Cancer and Research Institutes
      • 5.1.8.7.3. Clinics
      • 5.1.8.7.4. Others
    • 5.1.9. Canada
    • 5.1.10. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Vector
  • 6.3. By Gene Delivery Method
  • 6.4. By Application
  • 6.5. By Route of Administration
  • 6.6. By End-users
  • 6.7. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Bristol Myers Squibb Company
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Sarepta therapeutics Inc.
  • 13.3. Novartis AG
  • 13.4. Biogen Inc.
  • 13.5. Gilead Sciences Inc.
  • 13.6. Astellas Pharma Inc.
  • 13.7. F. Hoffmann-La Roche Ltd
  • 13.8. Sanofi S.A.
  • 13.9. Medtronic Inc.
  • 13.10. Takeda Pharmaceutical Company
  • 13.11. AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 3. Global Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 5. Global Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 6. Global Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 7. Global Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 8. Global Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 9. Global Gene Therapy Market Share (%), By Region, 2017-2031F
  • Figure 10. North America Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 11. North America Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 12. North America Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 13. North America Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 14. North America Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 15. North America Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 16. North America Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17. North America Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 18. North America Gene Therapy Market Share (%), By Country, 2017-2031F
  • Figure 19. United States Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. United States Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 21. United States Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 22. United States Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 23. United States Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 24. United States Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 25. United States Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26. United States Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 27. Canada Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Canada Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 29. Canada Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 30. Canada Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 31. Canada Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 32. Canada Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 33. Canada Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 34. Canada Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 35. Mexico Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 36. Mexico Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 37. Mexico Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 38. Mexico Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 39. Mexico Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 40. Mexico Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 41. Mexico Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 42. Mexico Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 43. Europe Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Europe Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 45. Europe Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 46. Europe Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 47. Europe Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 48. Europe Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 49. Europe Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 50. Europe Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 51. Europe Gene Therapy Market Share (%), By Country, 2017-2031F
  • Figure 52. Germany Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Germany Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 54. Germany Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 55. Germany Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 56. Germany Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 57. Germany Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 58. Germany Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 59. Germany Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 60. France Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. France Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 62. France Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 63. France Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 64. France Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 65. France Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 66. France Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 67. France Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 68. Italy Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 69. Italy Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 70. Italy Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 71. Italy Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 72. Italy Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 73. Italy Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 74. Italy Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75. Italy Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 76. United Kingdom Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. United Kingdom Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 78. United Kingdom Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 79. United Kingdom Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 80. United Kingdom Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 81. United Kingdom Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 82. United Kingdom Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83. United Kingdom Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 84. Russia Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Russia Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 86. Russia Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 87. Russia Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 88. Russia Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 89. Russia Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 90. Russia Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 91.
  • Figure 92. Russia Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 93. Netherlands Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 94. Netherlands Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 95. Netherlands Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 96. Netherlands Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 97. Netherlands Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 98. Netherlands Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 99. Netherlands Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 100. Netherlands Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 101. Spain Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Spain Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 103. Spain Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 104. Spain Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 105. Spain Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 106. Spain Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 107. Spain Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 108. Spain Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 109. Turkey Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. Turkey Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 111. Turkey Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 112. Turkey Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 113. Turkey Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 114. Turkey Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 115. Turkey Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 116. Turkey Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 117. Poland Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Poland Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 119. Poland Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 120. Poland Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 121. Poland Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 122. Poland Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 123. Poland Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 124. Poland Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 125. South America Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 126. South America Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 127. South America Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 128. South America Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 129. South America Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 130. South America Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 131. South America Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 132. South America Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 133. South America Gene Therapy Market Share (%), By Country, 2017-2031F
  • Figure 134. Brazil Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 135. Brazil Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 136. Brazil Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 137. Brazil Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 138. Brazil Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 139. Brazil Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 140. Brazil Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 141. Brazil Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 142. Argentina Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 143. Argentina Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 144. Argentina Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 145. Argentina Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 146. Argentina Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 147. Argentina Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 148. Argentina Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149. Argentina Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 150. Asia-Pacific Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. Asia-Pacific Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 152. Asia-Pacific Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 153. Asia-Pacific Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 154. Asia-Pacific Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 155. Asia-Pacific Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 156. Asia-Pacific Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 157. Asia-Pacific Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 158. Asia-Pacific Gene Therapy Market Share (%), By Country, 2017-2031F
  • Figure 159. India Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 160. India Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 161. India Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 162. India Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 163. India Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 164. India Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 165. India Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166. India Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 167. China Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. China Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 169. China Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 170. China Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 171. China Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 172. China Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 173. China Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 174. China Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 175. Japan Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Japan Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 177. Japan Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 178. Japan Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 179. Japan Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 180. Japan Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 181. Japan Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 182. Japan Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 183. Australia Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 184. Australia Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 185. Australia Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 186. Australia Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 187. Australia Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 188. Australia Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 189. Australia Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 190. Australia Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 191. Vietnam Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 192. Vietnam Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 193. Vietnam Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 194. Vietnam Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 195. Vietnam Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 196. Vietnam Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 197. Vietnam Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 198. Vietnam Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 199. South Korea Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 200. South Korea Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 201. South Korea Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 202. South Korea Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 203. South Korea Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 204. South Korea Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 205. South Korea Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 206. South Korea Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 207. Indonesia Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 208. Indonesia Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 209. Indonesia Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 210. Indonesia Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 211. Indonesia Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 212. Indonesia Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 213. Indonesia Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 214. Indonesia Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 215. Philippines Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 216. Philippines Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 217. Philippines Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 218. Philippines Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 219. Philippines Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 220. Philippines Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 221. Philippines Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 222. Philippines Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 223. Middle East & Africa Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 224. Middle East & Africa Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 225. Middle East & Africa Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 226. Middle East & Africa Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 227. Middle East & Africa Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 228. Middle East & Africa Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 229. Middle East & Africa Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 230. Middle East & Africa Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 231. Middle East & Africa Gene Therapy Market Share (%), By Country, 2017-2031F
  • Figure 232. Saudi Arabia Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 233. Saudi Arabia Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 234. Saudi Arabia Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 235. Saudi Arabia Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 236. Saudi Arabia Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 237. Saudi Arabia Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 238. Saudi Arabia Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 239. Saudi Arabia Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 240. UAE Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 241. UAE Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 242. UAE Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 243. UAE Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 244. UAE Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 245. UAE Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 246. UAE Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 247. UAE Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 248. South Africa Gene Therapy Market, By Value, In USD Billion, 2017-2031F
  • Figure 249. South Africa Gene Therapy Market, By Volume, In Units Thousand, 2017-2031F
  • Figure 250. South Africa Gene Therapy Market Share (%), By Type, 2017-2031F
  • Figure 251. South Africa Gene Therapy Market Share (%), By Vector, 2017-2031F
  • Figure 252. South Africa Gene Therapy Market Share (%), By Gene Delivery Method, 2017-2031F
  • Figure 253. South Africa Gene Therapy Market Share (%), By Application, 2017-2031F
  • Figure 254. South Africa Gene Therapy Market Share (%), By Route of Administration, 2017-2031F
  • Figure 255. South Africa Gene Therapy Market Share (%), By End-users, 2017-2031F
  • Figure 256. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 257. By Vector Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 258. By Gene Delivery Method Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 259. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 260. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 261. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023